218 related articles for article (PubMed ID: 16834658)
1. Clinical validity of proliferating cell nuclear antigen as an objective marker for evaluating biologic features in patients with untreated prostate cancer.
Miyamoto S; Ito K; Kurokawa K; Suzuki K; Suzuki K; Yamanaka H
Int J Urol; 2006 Jun; 13(6):767-72. PubMed ID: 16834658
[TBL] [Abstract][Full Text] [Related]
2. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
[TBL] [Abstract][Full Text] [Related]
3. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival.
Nakamura T; Tabuchi Y; Nakae S; Ohno M; Saitoh Y
Cancer; 1996 Apr; 77(8 Suppl):1741-6. PubMed ID: 8608572
[TBL] [Abstract][Full Text] [Related]
4. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
8. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma.
Wang LF; Chai CY; Kuo WR; Tai CF; Lee KW; Ho KY
Acta Otolaryngol; 2006 Jul; 126(7):769-74. PubMed ID: 16803719
[TBL] [Abstract][Full Text] [Related]
11. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
12. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
13. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
[TBL] [Abstract][Full Text] [Related]
14. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer.
Sulik M; Guzińska-Ustymowicz K
Rocz Akad Med Bialymst; 2002; 47():262-9. PubMed ID: 12533969
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
16. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
Shimizu Y; Segawa T; Inoue T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Terada N; Kobayashi T; Kinoshita H; Kamoto T; Nakamura E; Ogawa O
BJU Int; 2007 Sep; 100(3):685-90. PubMed ID: 17542985
[TBL] [Abstract][Full Text] [Related]
17. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
18. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta as a clinical biomarker for prostate cancer.
Perry KT; Anthony CT; Case T; Steiner MS
Urology; 1997 Jan; 49(1):151-5. PubMed ID: 9000208
[TBL] [Abstract][Full Text] [Related]
20. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]